Cancer immunotherapy in routine cost‐effective cancer care?

Therapy‐triggered autoimmunity and inflammation in many cancer patients, as well as treatment costs, hamper the success of cancer immunotherapy. The study by Pfeiffer et al in this issue of EMBO Molecular Medicine constitutes a clear step towards a more simple, scalable and affordable approach in ge...

Descripción completa

Detalles Bibliográficos
Autor principal: Feldmann, Sir Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
News & Views
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220302/
https://www.ncbi.nlm.nih.gov/pubmed/30322840
http://dx.doi.org/10.15252/emmm.201809660
_version_ 1783368799694618624
author Feldmann, Sir Marc
author_facet Feldmann, Sir Marc
author_sort Feldmann, Sir Marc
collection PubMed
description Therapy‐triggered autoimmunity and inflammation in many cancer patients, as well as treatment costs, hamper the success of cancer immunotherapy. The study by Pfeiffer et al in this issue of EMBO Molecular Medicine constitutes a clear step towards a more simple, scalable and affordable approach in generating in situ T cells reprogrammed with chimeric antigen receptors (CARs) (Pfeiffer et al, 2018).
format Online
Article
Text
id pubmed-6220302
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62203022018-11-15 Cancer immunotherapy in routine cost‐effective cancer care? Feldmann, Sir Marc EMBO Mol Med News & Views Therapy‐triggered autoimmunity and inflammation in many cancer patients, as well as treatment costs, hamper the success of cancer immunotherapy. The study by Pfeiffer et al in this issue of EMBO Molecular Medicine constitutes a clear step towards a more simple, scalable and affordable approach in generating in situ T cells reprogrammed with chimeric antigen receptors (CARs) (Pfeiffer et al, 2018). John Wiley and Sons Inc. 2018-10-15 2018-11 /pmc/articles/PMC6220302/ /pubmed/30322840 http://dx.doi.org/10.15252/emmm.201809660 Text en © 2018 The Author. Published under the terms of the CC BY 4.0 license This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle News & Views
Feldmann, Sir Marc
Cancer immunotherapy in routine cost‐effective cancer care?
title Cancer immunotherapy in routine cost‐effective cancer care?
title_full Cancer immunotherapy in routine cost‐effective cancer care?
title_fullStr Cancer immunotherapy in routine cost‐effective cancer care?
title_full_unstemmed Cancer immunotherapy in routine cost‐effective cancer care?
title_short Cancer immunotherapy in routine cost‐effective cancer care?
title_sort cancer immunotherapy in routine cost‐effective cancer care?
topic News & Views
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6220302/
https://www.ncbi.nlm.nih.gov/pubmed/30322840
http://dx.doi.org/10.15252/emmm.201809660
work_keys_str_mv AT feldmannsirmarc cancerimmunotherapyinroutinecosteffectivecancercare

Ejemplares similares